{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=human+albumin&page=2", "query": { "intervention": "human albumin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 194, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=human+albumin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=human+albumin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T00:16:20.005Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT04356859", "title": "The Acute Burn ResUscitation Multicenter Prospective Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Burn Injury" ], "interventions": [ { "name": "Albumin Human", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Burn Association", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2021-04-22", "completion_date": "2025-09-29", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Sacramento, California • Torrance, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04356859" }, { "nct_id": "NCT03181100", "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Thyroid Gland Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8", "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8", "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8", "Thyroid Gland Anaplastic Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2017-07-27", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03181100" }, { "nct_id": "NCT03818854", "title": "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Distress Syndrome, Adult" ], "interventions": [ { "name": "Human Mesenchymal Stromal Cells", "type": "BIOLOGICAL" }, { "name": "Cell Reconstitution Media", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Michael A. Matthay", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2019-11-26", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 7, "location_summary": "Sacramento, California • San Francisco, California • Portland, Oregon + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03818854" }, { "nct_id": "NCT01376778", "title": "A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Cytomegalovirus Infection", "Maternal Cytomegalovirus Infection" ], "interventions": [ { "name": "CMV hyperimmune globulin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "The George Washington University Biostatistics Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 399, "start_date": "2012-04", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376778" }, { "nct_id": "NCT00235495", "title": "Albumin in Acute Ischemic Stroke Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ischemic Stroke" ], "interventions": [ { "name": "Albumin", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "83 Years", "sex": "ALL", "summary": "18 Years to 83 Years" }, "enrollment_count": 841, "start_date": "2006-06", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 69, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235495" }, { "nct_id": "NCT00818662", "title": "A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer´s Disease" ], "interventions": [ { "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg", "type": "BIOLOGICAL" }, { "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg", "type": "BIOLOGICAL" }, { "name": "Placebo solution: Human Albumin 0.25% - 4 mL/kg", "type": "BIOLOGICAL" }, { "name": "Placebo solution: Human Albumin 0.25% - 2 mL/kg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 390, "start_date": "2008-12-19", "completion_date": "2012-12-10", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00818662" }, { "nct_id": "NCT04104672", "title": "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "AB680", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2019-11-06", "completion_date": "2026-07-21", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 9, "location_summary": "Santa Monica, California • St Louis, Missouri • New York, New York + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104672" }, { "nct_id": "NCT03886506", "title": "Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Critical Limb Ischemia (CLI)" ], "interventions": [ { "name": "PLX-PAD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pluristem Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "45 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "45 Years to 99 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 2, "location_summary": "Clifton, New Jersey • Teaneck, New Jersey", "locations": [ { "city": "Clifton", "state": "New Jersey" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886506" }, { "nct_id": "NCT00949663", "title": "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)", "type": "DRUG" }, { "name": "Xenin-25", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2009-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-07-22", "last_synced_at": "2026-10-01T00:16:20.005Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949663" } ] }